EP3645005A1 — Combination of a pi3k-inhibitor with an androgen receptor antagonist

USPTO Abstract

The invention relates to combinations of a component A which is an inhibitor of PI3K kinase, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture thereof, for example; a component B which is an androgen receptor antagonist, such as darolutamide or enzalutamide, for example; and, optionally, one or more pharmaceutical agents C. In said combinations, optionally component A and / or component B are in the form of a ready-to-use pharmaceutical formulation which is administered simultaneously, concurrently , separately or sequentially. The invention relates to the use of such combinations in the treatment or prophylaxis of cancer, in particular prostate cancer; or in the preparation of a medicament for the treatment or prophylaxis of cancer, particularly prostate cancer. It relates to methods of treating or preventing cancer, particularly prostate cancer, in a subject from administering to the subject a therapeutically effective amount of such a combination. It also relates to compositions containing such a combination, associated with pharmaceutically acceptable ingredients; and kits comprising such a combination.